Jump to content

Daniel Przybysz

Add links
From Wikipedia, the free encyclopedia
Daniel Przybysz, MD 2017[1]

Dr. Daniel Przybysz (born March 25, 1988) is a Brazilian Radiation-Oncologist. His practice is mainly focused on lung cancer treatment and high technology approaches toward better patient care

Przybysz has a medical degree from the Federal University of Parana, Brazil jointly with Harvard Medical School. He graduated in 2013 with high-honors after doing his internships in Oncology-related rotations.

After spending some time at the Massachusetts General Hospital in Boston and at the University of Texas MD Anderson Cancer Center, Przybysz began a Radiation-Oncology program at the Brazilian National Cancer Institute. He graduated residency and was invited to start a position as Visitor Researcher in Radiation-Oncology at the Washington University School of Medicine.

Przybysz also works as an Oncology Reviewer for UpToDate and as an author, editor and reviewer for lung-related articles at the International Journal of Radiation Oncology, Biology and Physics, contributing on high-level reviews for medical content.

Publications

[edit]

Przybysz's interest in clinical cancer research and outcomes has culminated in several publications, some of listed below:

  • Henke, Lauren E.; Kashani, Rojano; Przybysz, Daniel; Hilliard, Jessica; Curcuru, Austen; Green, Olga L.; Bradley, Jeffrey D.; Robinson, Clifford G. (2017-06-01). "(S009) In Silico Trial of MR-Guided Mid-Treatment Adaptive Planning for Hypofractionated Stereotactic Radiotherapy in Centrally Located Thoracic Tumors". International Journal of Radiation Oncology, Biology, Physics. 98 (2): E3. doi:10.1016/j.ijrobp.2017.02.045. ISSN 0360-3016.[2]
  • "Wednesday 31 May / ISRS - INTERNATIONAL STEREOTACTIC RADIOSURGERY SOCIETY". www.isrscongress.org. Retrieved 2017-08-07.[3]
  • Przybysz, Daniel; Bradley, Jeffrey D. (2017-06-01). "Challenging Situations for Lung SBRT". Journal of Thoracic Oncology. 12 (6): 916–918. doi:10.1016/j.jtho.2017.04.007. ISSN 1556-0864. PMID 28532561.[4]
  • Magnetic Resonance Image-Guided Radiation Therapy (MR-IGRT) for the Treatment of Prostate Cancer: Initial Patient Selection and Clinical Experience - Journal of Urology 2017[5]
  • Lung SBRT using MRI-guided radiation therapy: possible GTV changes and benefits of adaptive therapy In Silico Trial of MR-Guided Mid-Treatment Adaptive Planning for Hypofractionated Stereotactic Radiotherapy in Centrally Located Thoracic Tumors - IJROBP 2016[6]
  • Lung SBRT using MRI-guided radiation therapy: possible GTV changes and benefits of adaptive therapy - SBRT 2016[7]
  • Henke, L.; Przybysz, D.; Kashani, R.; Green, O.; Robinson, C.; Bradley, J. (April 2016). "EP-1225: MRI-defined GTV change during SBRT for unresectable or oligometastatic disease of the central thorax". Radiotherapy and Oncology. 119: S580–S581. doi:10.1016/S0167-8140(16)32475-6.[8]
  • A comparison between VMAT, IMRT and GAP techniques on the Medulloblastoma approach: different technologies aiming better patient care - Radiology 2015[9]
  • Potential benefits of Neoadjuvant Radiation Therapy On Overall Survival in Advanced Breast Cancer Patients - Radiology 2016[10]
  • Przybysz, D.; Hill, E. K.; Dizon, D. S. (2015-11-01). "Sexual Dysfunction After Cancer: Findings From the Program in Women's Oncology Center for Sexuality, Intimacy, and Fertility". International Journal of Radiation Oncology, Biology, Physics. 93 (3): E487. doi:10.1016/j.ijrobp.2015.07.1790. ISSN 0360-3016.[11]
  • Vieiralves, Yasmine; Przybysz, Daniel; et al. (31 May 2017). Visual outcomes predictors after stereotactic radiosurgery for choroidal melanomas. ISRS2017: International Stereotactic Radiosurgery Society. Retrieved 2017-08-07.[12]

Nevertheless, Przybysz is now developing projects using high-technology treatment planning towards better patient care. At present, he is engaged in several studies regarding lung cancer, CNS malignancies and prostate cancer.[13]

He has been recognized and awarded as a Leading Physician of The World by the International Association of Healthcare Providers in 2017.[14]

References

[edit]
  1. ^ "LinkedIn Profile".
  2. ^ "IJROBP 2017". doi:10.1016/j.ijrobp.2017.02.045. {{cite journal}}: Cite journal requires |journal= (help)
  3. ^ "ISRS 2017".
  4. ^ Przybysz, Daniel; Bradley, Jeffrey D. (June 2017). "JTO". Journal of Thoracic Oncology. 12 (6): 916–918. doi:10.1016/j.jtho.2017.04.007. PMID 28532561.
  5. ^ Fischer-Valuck, B. W.; Rao, Y. J.; Rudra, S.; Przybysz, D.; Germino, E.; Samson, P.; Baumann, B. C.; Gay, H.; Michalski, J. (2018). "Journal of Urology". 199 (2): 416–423. doi:10.1016/j.juro.2017.08.086. PMID 28842247. S2CID 26786207. {{cite journal}}: Cite journal requires |journal= (help)
  6. ^ Henke, Lauren E.; Kashani, Rojano; Przybysz, Daniel; Hilliard, Jessica; Curcuru, Austen; Green, Olga L.; Bradley, Jeffrey D.; Robinson, Clifford G. (June 2017). "Red Journal". International Journal of Radiation Oncology, Biology, Physics. 98 (2): E3. doi:10.1016/j.ijrobp.2017.02.045.
  7. ^ "SBRT 2016".
  8. ^ Henke, L.; Przybysz, D.; Kashani, R.; Green, O.; Robinson, C.; Bradley, J. (April 2016). "Green Journal". Radiotherapy and Oncology. 119: S580–S581. doi:10.1016/S0167-8140(16)32475-6.
  9. ^ "RSNA 2015".
  10. ^ "RSNA 2015".
  11. ^ Przybysz, D.; Hill, E. K.; Dizon, D. S. (November 2015). "IJROBP 2015". International Journal of Radiation Oncology, Biology, Physics. 93 (3): E487. doi:10.1016/j.ijrobp.2015.07.1790.
  12. ^ "ISRS 2017".
  13. ^ Przybysz, Daniel (7 August 2017). "LinkedIn Profile". LinkedInc.
  14. ^ "IAHCP Website".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Daniel_Przybysz&oldid=1191085967"